Clinical Study

Mallinckrodt Treatment Of Proteinuria Due To Idiopathic Focal Segmental Glomerulosclerosis With Ho Acthar Gel

Posted Date: Feb 17, 2018

  • Investigator: Shashi Kant
  • Specialties:
  • Type of Study: Drug

Focal Segmental Glomerulosclerosis (FSGS) is a rare disease caused by the scarring of sections of your kidneys (glomeruli). Each kidney is made up of several glomeruli that aid the body in filtering waste products from the blood. This waste is removed from the body in the form of urine. When the glomeruli become scarred, the filtering mechanism does not work correctly resulting in the leakage of protein into the urine. The purpose of this study is to examine the effects of this study medication for FSGS.

Criteria:

Signed Consent, Men And Women Either Not Of Child-Bearing Potential Or Willing To Use Birth Control. Fsgs Proven By Renal Biopsy Within Last Three Years, Upcr >3500 Mg/G, Egfr >=30, And Failed To Achieve Partial Or Complete Remission Of Proteinuria With At Least One But Not More Than 2 Two Prior Immunosuppressive Therapies, Treated With Acei, Arb Or Dri For More Than 4 Weeks, Bp Less Than 150/90. Diabetes, Active Liver Disease, History Or Current Tuberculosis And Other Medical Conditions May Be Exclusionary.

Keywords:

Chronic Kidney Disease, Focal Segmental Glomerulosclerosis, Proteinuria

For More Information:

Karen Case, Ccrp
(513) 559-3367
karen.case@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.